Safety and efficacy of non-vitamin K oral anticoagulants in non-valvular atrial fibrillation: A Bayesian meta-analysis approach

Expert Opinion on Drug Safety

Volumn 14, Issue 1, 2015, Pages 7-20

  Verdecchia, Paolo ^a   Angeli, Fabio ^b   Bartolini, Claudia ^a   De Filippo, Valentina ^a   Aita, Adolfo ^a   Di Giacomo, Letizia ^a   Poltronieri, Cristina ^b   Lip, Gregory YH ^c   Reboldi, Gianpaolo ^d  

^a Hospital of Assisi Department of Medicine ^*  (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Apixaban; Atrial fibrillation; Bleeding; Dabigatran; Edoxaban; Mortality; Rivaroxaban; Stroke; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; WARFARIN;

ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; DRUG EFFICACY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; META ANALYSIS; MORTALITY; NON VALVULAR ATRIAL FIBRILLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); AGED; ATRIAL FIBRILLATION; BAYES THEOREM; CHEMICALLY INDUCED; FEMALE; MALE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BAYES THEOREM; CEREBRAL HEMORRHAGE; FEMALE; HUMANS; MALE;

EID: 84918533334     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.971009     Document Type: Article

References (44)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8
2. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019-26
3. Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med 2007;147:590-2
4. De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on thrombosis - task force on anticoagulants in heart disease. Thromb Haemost 2013;110:1087-107
5. Wilke T, Groth A, Mueller S, et al. Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients. Thromb Haemost 2012;107:1053-65
6. Husted S, de Caterina R. . ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel. Thromb Haemost 2014;111:781-2
7. De Caterina R, Husted S, Wallentin L, et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on thrombosis-task force on anticoagulants in heart disease position paper. J Am Coll Cardiol 2012;59:1413-25
8. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
9. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91
10. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92
11. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-104
12. Lip GY, Larsen TB, Skjoth F, Rasmussen LH. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2012;60:738-46
13. Rasmussen LH, Larsen TB, Graungaard T, et al. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. BMJ 2012;345:e7097
14. Baker WL, Phung OJ. Systematic review and adjusted indirect comparison metaanalysis of oral anticoagulants in atrial fibrillation. Circ Cardiovasc Qual Outcomes 2012;5:711-19
15. Mantha S, Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost 2012;108:476-84
16. Harenberg J, Marx S, Diener HC, et al. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. Int Angiol 2012;31:330-9
17. Sardar P, Chatterjee S, Wu WC, et al. New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons. PLoS One 2013;8:e77694
18. Skjoth F, Larsen TB, Rasmussen LH, Lip GY. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thromb Haemost 2014;111:981-8
19. Verdecchia P, Angeli F, Lip GY, Reboldi G. Edoxaban in the evolving scenario of non vitamin k antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons. PLoS One 2014;9:e100478
20. Cannon CP, Kohli P. Danger ahead: watch out for indirect comparisons. J Am Coll Cardiol 2012;60:747-8
21. Skjoth F, Larsen TB, Rasmussen LH. Indirect comparison studies - Are they useful?. Insights from the novel oral anticoagulants for stroke prevention in atrial fibrillation. Thromb Haemost 2012;108:405-6
22. Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR. Bayesian methods in health technology assessment: a review. Health Technol Assess 2000;4:1-130
23. Sutton AJ, Abrams KR. Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res 2001;10:277-303
24. Cameron C, Coyle D, Richter T, et al. Systematic review and network metaanalysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. BMJ Open 2014;4:e004301
25. Dogliotti A, Paolasso E, Giugliano RP. Current and new oral antithrombotics in non-valvular atrial fibrillation: a network meta-analysis of 79 808 patients. Heart 2014;100:396-405
26. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100
27. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RELY trial. N Engl J Med 2010;363:1875-6
28. Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 2011;14:429-37
29. Spiegelhalter DJ, Best NG, Carlin BP, van Der Linde A. Bayesian measures of model complexity and fit. J R Stat Soc 2002;64:583-639
30. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011;64:163-71
31. Assiri A, Al-Majzoub O, Kanaan AO, et al. Mixed treatment comparison metaanalysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation. Clin Ther 2013;35:967-984.e2
32. Snapinn S, Jiang Q. Indirect comparisons in the comparative efficacy and non-inferiority settings. Pharm Stat 2011;10:420-6
33. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-47
34. Pisters R, Nieuwlaat R, Lane DA, et al. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey. Thromb Haemost 2013;109:328-36
35. Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a real world atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012;107:584-9
36. Cohen D. Dabigatran: how the drug company withheld important analyses. BMJ 2014;349:g4670
37. Reilly PA, Connolly SJ, Yusuf S, et al. Reply: regarding the effect of dabigatran plasma concentrations. J Am Coll Cardiol 2014;63:2885-6
38. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003;326:472
39. ONeil WM, Welner SA, Lip GY. Do open label blinded outcome studies of novel anticoagulants versus warfarin have equivalent validity to those carried out under double-blind conditions?. Thromb Haemost 2013;109:497-503
40. Hylek EM, Ko D, Cove CL. Gaps in translation from trials to practice: nonvitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation. Thromb Haemost 2014;111:783-8
41. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 2010;341:c3666
42. Rosand J, Hylek EM, ODonnell HC, Greenberg SM. Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology 2000;55:947-51
43. Lovelock CE, Cordonnier C, Naka H, et al. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: a systematic review of published and unpublished studies. Stroke 2010;41:1222-8
44. Poels MM, Vernooij MW, Ikram MA, et al. Prevalence and risk factors of cerebral microbleeds: an update of the Rotterdam scan study. Stroke 2010;41:S103-6